Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients

CHENG Ying; ZHANG Liang

doi:10.12019/j.issn.1671-5144.2023.04.005

CHENG Ying, ZHANG Liang. Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005

Citation:

CHENG Ying, ZHANG Liang. Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005

Citation:

CHENG Ying, ZHANG Liang. Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients[J]. Journal of Evidence-Based Medicine, 2023, 23(4): 213-224. DOI: 10.12019/j.issn.1671-5144.2023.04.005

Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients

Graphical Abstract

Abstract

FullText(HTML)

References (14)

Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor PD-L1 Expression in Asian Patients

Catalog

Export File

Citation

Format

Content